Evidence map›Paper›PMID 34427073›Full record

ArticleYonsei medical journal2021

Role of NEAT1/MiR-9-5p/SLC26A2 Pathway on Human Airway Smooth Muscle Cell.

Xiangying Wang, Ruju Xu, Di Chi, Chufeng Dai, Meiling Sheng

Open access · goldAbstract read
In one paragraph

Article in Yonsei medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. LAPTM5 potentiates airway remodeling by regulating MAPKs-mediated airway smooth muscle cells' dysfunction.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Noncoding RNAs in asthmatic airway smooth muscle cells.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiangying WangDepartment of Rheumatology and Immunology in Children, Hangzhou Children's Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0002-2753-1333
Ruju XuDepartment of Rheumatology and Immunology in Children, Hangzhou Children's Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0002-1385-3235
Di ChiDepartment of Rheumatology and Immunology in Children, Hangzhou Children's Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0003-0086-5568
Chufeng DaiDepartment of Rheumatology and Immunology in Children, Hangzhou Children's Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0001-5621-3142
Meiling ShengDepartment of Rheumatology and Immunology in Children, Hangzhou Children's Hospital, Hangzhou, China. niiww1986@126.com.ORCID https://orcid.org/0000-0002-7647-3299
Hangzhou Children's Hospital · CN

Funding

Zhejiang Medical and Health Science and Technology Plan Project
6 · The paper itself

Abstract

purposeAsthma is a serious inflammatory disease of the respiratory system in which airway smooth muscle cells (ASMCs) play a key role. This study aimed to investigate the expression of SLC26A2 in human ASMCs (HASMCs) and the regulatory mechanism of SLC26A2 in the proliferation and inflammatory factor production of HASMCs. MATERIALS AND

methodsWe obtained the asthma-associated differential mRNA SLC26A2 by bioinformatics analysis in childhood acute asthma samples. To investigate its role in airway inflammation and airway remodeling, we treated HASMCs with platelet-derived growth factor (PDGF) in an in vitro model and determined SLC26A2 expression in cells using western blotting. Cell proliferation was detected by MTT and EdU assays, and cell contractile phenotype marker proteins were measured. Cell migration and production of inflammatory factors were determined by Transwell and ELISA assays. Additionally, the upstream regulatory miRNA and LncRNA of SLC26A2 were identified by bioinformatics, luciferase reporter gene, and RIP analyses.

resultsSLC26A2 was significantly upregulated in bioinformatics analysis of pediatric asthma-related sample. PDGF treatment up-regulated SLC26A2 expression in HASMCs, whereas the knockdown of SLC26A2 inhibited PDGF-stimulated proliferation, migration, and production of inflammatory factors, and enhanced the expression of cell contractile phenotype marker proteins in HASMCs. Luciferase reporter and RIP experiments validated that NEAT1 targeted miR-9-5p to regulate SLC26A2, thereby influencing the biological function of PDGF-induced HASMCs.

conclusionThese findings indicate that NEAT1-mediated miR-9-5p targeting of SLC26A2 inhibits the PDGF-induced proliferation and production of inflammatory factors in HASMCs. These findings highlight potential therapeutic targets for asthma and airway inflammation.

Indexed as

MicroRNAsCell MovementCell ProliferationChildHumansMyocytes, Smooth MuscleRespiratory SystemSulfate TransportersMicroRNAsSLC26A2 protein, humanSulfate Transportersairway smooth muscle cellsasthmainflammatory factorsmiR-9-5pNEAT1platelet-derived growth factorproliferationSLC26A2

Identifiers

PMID34427073
PMCPMC8382724
OpenAlexW3194433447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.